REGENXBIO (RGNX) News Today → Crypto Pioneer Says: “The last crypto bull market has begun.” (From InvestorPlace) (Ad) Free RGNX Stock Alerts $15.99 -0.02 (-0.12%) (As of 05/17/2024 08:54 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 19 at 5:30 AM | americanbankingnews.comHC Wainwright Raises REGENXBIO (NASDAQ:RGNX) Price Target to $38.00May 18 at 6:42 AM | insidertrades.comKenneth T. Mills Sells 15,000 Shares of REGENXBIO Inc. (NASDAQ:RGNX) StockMay 18 at 1:44 AM | americanbankingnews.comEquities Analysts Offer Predictions for REGENXBIO Inc.'s Q2 2024 Earnings (NASDAQ:RGNX)May 17 at 12:11 PM | insidertrades.comREGENXBIO Inc. (NASDAQ:RGNX) CEO Sells $237,150.00 in StockMay 17 at 7:09 AM | marketbeat.comQ2 2024 Earnings Forecast for REGENXBIO Inc. Issued By HC Wainwright (NASDAQ:RGNX)REGENXBIO Inc. (NASDAQ:RGNX - Free Report) - Equities researchers at HC Wainwright lifted their Q2 2024 EPS estimates for REGENXBIO in a research report issued to clients and investors on Wednesday, May 15th. HC Wainwright analyst Y. Chen now expects that the biotechnology company will earn ($1.2May 16, 2024 | marketbeat.comInsider Selling: REGENXBIO Inc. (NASDAQ:RGNX) CEO Sells 15,000 Shares of StockREGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) CEO Kenneth T. Mills sold 15,000 shares of the business's stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $15.81, for a total value of $237,150.00. Following the completion of the transaction, the chief executive officer now directly owns 408,035 shares of the company's stock, valued at $6,451,033.35. The transaction was disclosed in a legal filing with the SEC, which is available at this link.May 15, 2024 | markets.businessinsider.comEvaluating Regenxbio: Insights From 9 Financial AnalystsMay 15, 2024 | marketbeat.comHC Wainwright Increases REGENXBIO (NASDAQ:RGNX) Price Target to $38.00HC Wainwright raised their price objective on REGENXBIO from $36.00 to $38.00 and gave the company a "buy" rating in a research report on Wednesday.May 13, 2024 | americanbankingnews.comREGENXBIO Inc. to Post Q2 2024 Earnings of ($1.19) Per Share, Leerink Partnrs Forecasts (NASDAQ:RGNX)May 11, 2024 | finance.yahoo.comAnalysts Have Lowered Expectations For REGENXBIO Inc. (NASDAQ:RGNX) After Its Latest ResultsMay 10, 2024 | finance.yahoo.comRegenxbio Inc (RGNX) Q1 2024 Earnings: Misses Analyst Revenue and EPS ForecastsMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for RegenXBio Amid Promising Drug Developments and Solid FinancialsMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for RegenXBio on Clinical Progress and Promising Therapeutic CandidatesMay 10, 2024 | prnewswire.comREGENXBIO to Participate in Upcoming Investor ConferencesMay 9, 2024 | finance.yahoo.comREGENXBIO Inc. (NASDAQ:RGNX) Q1 2024 Earnings Call TranscriptMay 9, 2024 | marketbeat.comREGENXBIO (NASDAQ:RGNX) Posts Earnings Results, Misses Estimates By $0.10 EPSREGENXBIO (NASDAQ:RGNX - Get Free Report) posted its quarterly earnings results on Wednesday. The biotechnology company reported ($1.38) EPS for the quarter, missing analysts' consensus estimates of ($1.28) by ($0.10). The business had revenue of $15.60 million for the quarter, compared to the consensus estimate of $23.52 million. REGENXBIO had a negative return on equity of 68.18% and a negative net margin of 291.99%. The company's revenue for the quarter was down 18.3% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.53) EPS.May 9, 2024 | finance.yahoo.comRegenxbio Inc (RGNX) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress and Robust ...May 8, 2024 | prnewswire.comREGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational HighlightsMay 8, 2024 | marketbeat.comREGENXBIO (NASDAQ:RGNX) Downgraded by StockNews.comStockNews.com downgraded shares of REGENXBIO from a "hold" rating to a "sell" rating in a research report on Tuesday.May 7, 2024 | markets.businessinsider.comREGENXBIO earnings: here's what Wall Street expectsMay 2, 2024 | marketbeat.comREGENXBIO (RGNX) Set to Announce Quarterly Earnings on WednesdayREGENXBIO (NASDAQ:RGNX) will be releasing earnings after the market closes on Wednesday, May 8, Zacks reports.May 1, 2024 | prnewswire.comREGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational HighlightsApril 24, 2024 | prnewswire.comREGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing SummitApril 23, 2024 | marketbeat.comREGENXBIO Inc. (NASDAQ:RGNX) Shares Sold by Raymond James & AssociatesRaymond James & Associates cut its stake in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 49.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 50,537 shares of the biotechnology company's stock after selling 50,083 shaApril 21, 2024 | marketbeat.comMirae Asset Global Investments Co. Ltd. Reduces Holdings in REGENXBIO Inc. (NASDAQ:RGNX)Mirae Asset Global Investments Co. Ltd. trimmed its position in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 54.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 94,418 shares of the biotechnology company's stockApril 18, 2024 | marketbeat.comREGENXBIO (NASDAQ:RGNX) Shares Down 3.1% Following Insider SellingREGENXBIO (NASDAQ:RGNX) Shares Down 3.1% on Insider SellingApril 17, 2024 | finance.yahoo.comREGENXBIO Inc.'s (NASDAQ:RGNX) recent 7.9% pullback adds to one-year year losses, institutional owners may take drastic measuresApril 12, 2024 | markets.businessinsider.comWhere Regenxbio Stands With AnalystsApril 12, 2024 | marketbeat.comREGENXBIO (NASDAQ:RGNX) Earns "Buy" Rating from Stifel NicolausStifel Nicolaus reiterated a "buy" rating and issued a $40.00 price target on shares of REGENXBIO in a research note on Friday.April 6, 2024 | marketbeat.comREGENXBIO Inc. (NASDAQ:RGNX) Receives Average Recommendation of "Moderate Buy" from BrokeragesREGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the twelve ratings firms that are currently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and ten have assigned a buy recomApril 5, 2024 | marketbeat.comAssenagon Asset Management S.A. Invests $1.92 Million in REGENXBIO Inc. (NASDAQ:RGNX)Assenagon Asset Management S.A. bought a new stake in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 106,682 shares of the biotechnology company's stock, vMarch 31, 2024 | benzinga.comRegenxbio Stock (NASDAQ:RGNX), Quotes and News SummaryMarch 28, 2024 | marketbeat.comREGENXBIO (NASDAQ:RGNX) Stock Price Down 2%REGENXBIO (NASDAQ:RGNX) Stock Price Down 2%March 28, 2024 | finance.yahoo.comREGENXBIO Sees Positive Results For Macular Degeneration TherapyMarch 28, 2024 | prnewswire.comREGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMDMarch 27, 2024 | finance.yahoo.comREGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy DaysMarch 21, 2024 | marketbeat.comREGENXBIO (NASDAQ:RGNX) Raised to Hold at StockNews.comStockNews.com upgraded REGENXBIO from a "sell" rating to a "hold" rating in a report on Thursday.March 19, 2024 | insidertrades.comREGENXBIO Inc. (NASDAQ:RGNX) CEO Sells $327,900.00 in StockMarch 18, 2024 | finance.yahoo.comRegenxbio Inc (RGNX) President and CEO Kenneth Mills Sells 15,000 SharesMarch 17, 2024 | insidertrades.comREGENXBIO Inc. (NASDAQ:RGNX) Insider Steve Pakola Sells 12,878 SharesMarch 14, 2024 | marketbeat.comChardan Capital Comments on REGENXBIO Inc.'s FY2024 Earnings (NASDAQ:RGNX)REGENXBIO Inc. (NASDAQ:RGNX - Free Report) - Equities research analysts at Chardan Capital reduced their FY2024 earnings per share (EPS) estimates for shares of REGENXBIO in a report issued on Monday, March 11th. Chardan Capital analyst D. Gataulin now anticipates that the biotechnology company wMarch 12, 2024 | bizjournals.comRockville biotech raises $140M following layoffs, program cutsMarch 11, 2024 | marketbeat.comREGENXBIO (NASDAQ:RGNX) Upgraded at StockNews.comStockNews.com raised shares of REGENXBIO from a "sell" rating to a "hold" rating in a research report on Monday.March 11, 2024 | seekingalpha.comRegenxbio: DMD Program Lends Additional Credibility To NAV Technology PlatformMarch 11, 2024 | realmoney.thestreet.comRegenxbio initiated with bullish view at H.C. Wainwright, here's whyMarch 11, 2024 | marketbeat.comHC Wainwright Initiates Coverage on REGENXBIO (NASDAQ:RGNX)HC Wainwright assumed coverage on shares of REGENXBIO in a research note on Monday. They issued a "buy" rating and a $36.00 price objective for the company.March 11, 2024 | prnewswire.comREGENXBIO to Participate in Upcoming Investor ConferencesMarch 11, 2024 | marketbeat.comLeerink Partnrs Equities Analysts Boost Earnings Estimates for REGENXBIO Inc. (NASDAQ:RGNX)REGENXBIO Inc. (NASDAQ:RGNX - Free Report) - Leerink Partnrs boosted their Q1 2024 earnings per share (EPS) estimates for REGENXBIO in a research note issued on Thursday, March 7th. Leerink Partnrs analyst M. Foroohar now forecasts that the biotechnology company will post earnings of ($1.11) perMarch 8, 2024 | realmoney.thestreet.comRBC Capital gets more bullish on Regenxbio, upgrades sharesMarch 8, 2024 | realmoney.thestreet.comRBC Capital upgrades Regenxbio to Outperform, sees positive risk-reward Get REGENXBIO News Delivered to You Automatically Sign up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter. Email Address Crypto Pioneer Says: “The last crypto bull market has begun.” (Ad)Right now, there’s over $6 trillion in potential investment money waiting on the sidelines. That means this crypto bull market has a lot more room to run before it comes close to being a bubble. Click here if you’d like to learn more about these five cryptos… RGNX Media Mentions By Week RGNX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RGNX News Sentiment▼0.410.42▲Average Medical News Sentiment RGNX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RGNX Articles This Week▼154▲RGNX Articles Average Week Get REGENXBIO News Delivered to You Automatically Sign up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CRGX News RLAY News IMTX News MESO News HLVX News PRME News NVAX News EXAI News AUTL News CABA News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RGNX) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaNext President (Not Trump. Not Biden.)The Freeport SocietyUrgent Nvidia WarningAltimetryElon’s New Device is About to Shock the WorldInvestorPlace"The Biggest Drug Ever" Is ComingBehind the MarketsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding REGENXBIO Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
